Allergy Therapeutics plc

Allergy Therapeutics plc

AGYTF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$756.3M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Allergy Therapeutics plcAllergy Therapeutics plc-1.5-892%--6.5
$-0.12

Current Fair Value

183.1% downside

Overvalued by 183.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$756.30 Million
Enterprise Value$798.78 Million
Earnings per Share$-0.01
Beta0.83
Outstanding Shares5,224,773,000

Return

Return on Equity891.64%ROE
Return on Assets-106.00%
Return on Invested Capital-111.90%

Valuation & Multiples

P/E Ratio-1.5P/E Ratio
PEG-15.78PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.15Price to Book Ratio
Enterprise Value to Revenue6.42
Enterprise Value to EBIT-11.22
Enterprise Value to Net Income-9
Total Debt to Enterprise0.08
Debt to Equity-6.46Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$0.01
Est. -$0.01
Revenue
$31.64 M
Est. $35.42 M

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Allergy Therapeutics plc

584 employees
CEO: Manuel Llobet

Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, ...